The Pharma Data

NOVEMBER 30, 2020

Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. Vaccines Taskforce and National Institute for Health Research played pivotal roles in the rapid recruitment and enrollment of volunteers.

Clinical Development 52

Clinical Development Vaccination Vaccine Development 52

Drug Discovery World

MAY 23, 2024

A team of scientists in the US and the UK are combining a genetically modified cold sore virus with a cancer vaccine to treat an aggressive type of brain cancer in children. The researchers will use a genetically engineered herpes simplex virus type 1 to eliminate cancer cells.

Genetic Engineering 59

Genetic Engineering Engineer Immune Response Vaccination 59

Pharmaceutical Technology

AUGUST 17, 2022

Biopharmaceutical contract development and manufacturing organisation (CDMO) AGC Biologics has entered a strategic collaboration with RoosterBio to expedite the manufacturing of cell and exosome therapies. These capabilities comprise cell and exosome genetic engineering for expressing therapeutic targets.

Manufacturing 130

Manufacturing Gene Therapy Genetic Engineering Gene 130

Pharmaceutical Technology

MAY 2, 2023

IO agents include the classes of immune checkpoint modulators, cell therapies, bispecific antibodies, oncolytic viruses, therapeutic vaccines, and cytokines. All currently approved CAR-Ts are autologous, with the patient’s T-cells being genetically engineered to target antigens expressed by the cancerous cells.

Genetic Engineering 130

Genetic Engineering Antibody Clinical Trials Clinical Trials 130

Drug Discovery World

MARCH 21, 2023

In a step forward for genetic engineering and synthetic biology, US researchers have modified E coli bacteria to be immune to infection by all natural viruses tested so far. Genetic engineering The findings build on earlier efforts by genetic engineers, which involved genetically reprogramming E.

Engineer 52

Engineer Genetic Engineering Scientist Bacteria 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. IgG antibody responses are a useful marker of antigen exposure to diagnose immunodeficiency.

Gene Expression 130

Gene Expression Gene Genetic Engineering Antibody 130

Advarra

AUGUST 10, 2023

Gene therapy has achieved notable successes, particularly in treating resistant or refractory B cell leukemias (achieving overall response rates around 90% or greater) and the speed with which COVID-19 vaccines were developed under the original Operation Warp Speed. Why Warp Speed for Rare Diseases? What is the FDA Proposing to do?

Gene Therapy 52

Gene Therapy Development Gene Drugs 52

The Pharma Data

NOVEMBER 9, 2020

(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for NVX-CoV2373, the Company’s COVID-19 vaccine candidate. President of Research and Development, Novavax.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

Pharmaceutical Technology

JUNE 4, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Encoded Therapeutics develops gene therapies for the treatment of severe genetic disorders.

Gene 262

Gene Gene Therapy Genetics DNA 262

pharmaphorum

FEBRUARY 18, 2021

The South African coronavirus variant may cut the effectiveness of Pfizer/BioNTech’s vaccine by around two thirds, according to a laboratory study. In a response statement Pfizer and BioNTech noted that the COVID-19 vaccine did still provide protection in the lab study.

Immune Response 52

Immune Response Genetic Engineering Vaccination Vaccine 52

Advarra

MARCH 31, 2023

The use of engineered genetic materials in clinical trials is rapidly expanding, with potential applications for genetic vaccines, gene-modified cellular therapies, and gene therapies. A key part of the IBC’s evaluation is assessing the risks posed by the engineered genetic materials.

Engineer 52

Engineer Genetics Clinical Research Research 52

The Pharma Data

DECEMBER 16, 2020

Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an Advance Purchase Agreement with the government of New Zealand for the purchase of 10.7 million doses of NVX-CoV2373, Novavax’ candidate vaccine against COVID-19. GAITHERSBURG, Md.,

Protein 52

Protein Vaccination Vaccine Immune Response 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Nucleases are enzymes that hydrolytically cleave the phosphodiester backbone of DNA.

Gene Splicing 130

Gene Splicing Gene Recombinant DNA Technology DNA 130

pharmaphorum

MARCH 10, 2021

A laboratory study suggests Pfizer and BioNTech’s COVID-19 vaccine Comirnaty could be effective against a Brazilian variant of the SARS-CoV-2 virus – known as P.1 In February, the FDA issued guidelines allowing for faster development of updated coronavirus vaccines, while the EMA is also working on similar guidance for Europe.

Vaccination 58

Vaccination Vaccine Genetic Engineering Engineer 58

Roots Analysis

FEBRUARY 26, 2024

Over the next few decades, the identification of various pathogenic strains of microorganisms validated Koch’s assumptions and led to the development of more specific forms of therapy. Despite the widespread success of such interventions, certain limitations and drawbacks necessitated further research to develop better alternatives.

Genetics 52

Genetics Medicine Genetic Engineering Genetic Disease 52

Roots Analysis

FEBRUARY 13, 2023

With the help of genetic engineering, synthetic mRNAs can express proteins, as they structurally resemble a natural mRNA. Presently, more than 195 mRNA therapeutics / mRNA vaccines are under development or commercialized for the treatment of a variety of indications.

Manufacturing 52

Manufacturing Drug Delivery Systems Genetic Engineering RNA 52

Drug Discovery World

NOVEMBER 27, 2023

Across the biotherapeutics workflow The landscape of large molecule drug development has evolved significantly in recent decades. Technological innovations supporting discovery and development stages have concentrated on both upstream and downstream aspects of the workflow. This article is sponsored by Revvity.

Production 59

Production Engineer Gene Editing Gene 59

The Pharma Data

JUNE 25, 2021

Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% “Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines. Glenn, M.D.,

Vaccination 40

Vaccination Vaccine Trials Immune Response 40

Pharmaceutical Technology

MAY 8, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. The company's lead asset involving this technology is isaralgagene civaparvovec (ST 920).

Genetics 130

Genetics DNA Genetic Engineering Antibody 130

WCG Clinical

MAY 28, 2024

CAR-T Cells Target Harmful B Cells in Lupus CAR-T cell technology, which uses genetic engineering to direct white blood cells to attack specific molecular targets, was originally proposed for treatment of HIV infection and hematological malignancies.

In-Vivo 52

In-Vivo Clinical Trials Clinical Trials FDA Approval 52

Drug Discovery World

MAY 25, 2023

Following the Scottish Research and Drug Development Forum meeting, DDW’s Diana Spencer provides a snapshot of drug discovery in Scotland. Using complex models of cancer for preclinical testing After a coffee break, Prof Sansom was back behind the podium talking about the MRC National Mouse Genetics Network.

Research 52

Research Drugs In-Vitro Insulin 52

Drug Discovery World

FEBRUARY 15, 2023

Genetically modified T cells stimulated with IL2 are now administered as cell therapy for multiple cancer cell types with beneficial results 3,4. Further discovery of PD-1 and CTLA4 as negative immune regulators led to the development of a new class of cancer therapeutics, namely the immune checkpoint inhibitors 5,6.

Research 52

Research In-Vitro In-Vivo Development 52

The Pharma Data

SEPTEMBER 8, 2020

Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines. FDA has established clear guidance for the development of COVID-19 vaccines and clear criteria for their potential authorization or approval in the US.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

The Pharma Data

SEPTEMBER 8, 2020

— Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines. FDA has established clear guidance for the development of COVID-19 vaccines and clear criteria for their potential authorization or approval in the US.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

pharmaphorum

JANUARY 10, 2022

There are still licensing deals to be done in the COVID-19 category it seems, after Novartis paid around $163 million to license rights to an antiviral drug developed by Molecular Partners. Ensovibep has the potential to become the first multi-specific antiviral molecule for the treatment of COVID-19, according to Novartis.

Trials 52

Trials Drugs Antibody Genetic Engineering 52

The Pharma Data

OCTOBER 27, 2020

28, 2020 /PRNewswire/ — Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces the formation of a new Scientific Advisory Board (SAB). OSLO, Norway , Oct. Fennel cover the key scientific focus areas of Targovax. Dean A.

Antibody 52

Antibody Genetic Engineering Engineer Development 52

Drug Discovery World

NOVEMBER 8, 2023

On Day 1, Tuesday 14 November 2023, the tracks include: Display of biologics, antibody-based cancer therapies, safety and efficacy of bispecific antibodies, modulating the tumour microenvironment, optimisation and developability, and cell line and systems engineering.

Antibody 64

Antibody Engineer Protein Scientist 64

The Pharma Data

MARCH 29, 2022

Published today in Nature, the research opens the door to developing a therapeutic spray for humans. The small molecule was developed by Drs. “Our unpublished results represent encouraging findings with the current rapid propagation of Omicron BA.2 2 around the world.”

Genetic Engineering 52

Genetic Engineering Research Genetics Drugs 52

The Pharma Data

JANUARY 24, 2021

25, 2021 /PRNewswire/ — Elasmogen Ltd , the pioneering biopharmaceutical company leading the development of VNAR and soloMER biologics, today announces a significant breakthrough in the identification of next-generation protein-based drugs potentially capable of stopping COVID-19 infections. ABERDEEN, Scotland , Jan.

Antibody 52

Antibody Protein Research Genetic Engineering 52

Roots Analysis

OCTOBER 22, 2023

It is important to highlight that IVT mRNAs are structurally similar to natural mRNAs and can be used to express proteins through genetic engineering. Furthermore, these drug candidates can be used to develop precise and individualized therapies that allow patients to produce therapeutic proteins in their own bodies.

RNA 40

RNA Protein Genetics Gene Expression 40

Drug Discovery World

JULY 22, 2022

hIL15 immunodeficient mice are emerging as potential models for investigating these therapies based on IL15’s involvement with NK cell development 18. Researchers are beginning to answer this question by extending the utility of current models and developing more clinically relevant models to test therapies. After earning a B.A.

In-Vivo 52

In-Vivo Engineer In-Vitro Antibody 52

XTalks

AUGUST 17, 2020

Immunotherapy continues to be a burgeoning field, with immune-based therapies being among the leading treatments being developed in oncology and autoimmunity. protein-based biologics) and vaccine treatments. Treatment vaccines : these boost the immune system responses to target cells. Immune system modulators (i.e.

Protein 98

Protein Engineer Immune Response In-Vivo 98